- In August 2024, Azitra, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ATR-04, enabling the initiation of a first-in-human Phase 1/2 clinical trial targeting moderate to severe EGFR inhibitor-associated dermal toxicity
- In March 2022, Virpax has concluded all essential pre-clinical investigations, including assessments for dermal toxicity, for their experimental topical spray analgesic named Epoladerm. This product is designed to address chronic pain linked with knee osteoarthritis, potentially offering relief to affected patients
